# Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

> **NCT00050323** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 30 (—)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Allogeneic DCs and Autologous RCC Tumor Derived Cells

## Key facts

- **NCT ID:** NCT00050323
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2004-03
- **Target enrollment:** 30 (—)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00050323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00050323, "Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00050323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*